Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-09 21:40 | 2026-06-09 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $67.98 | 3,500 | $237,930 | 153,902 |
| 2026-06-09 21:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $19.45 | 10,500 | $204,260 | 43,415 |
| 2026-06-09 21:40 | 2026-06-05 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | SELL | $19.41 | 10,500 | $203,820 | 32,915 |
| 2026-06-09 21:30 | 2026-06-09 | TNXP | Tonix Pharmaceuticals Holding Corp. | LEDERMAN SETH | Director, Officer | BUY | $11.79 | 5,000 | $58,950 | 9,005 |
| 2026-06-09 21:30 | 2026-06-08 | TNXP | Tonix Pharmaceuticals Holding Corp. | Stillwell Richard Newcomb | Director | BUY | $11.65 | 5,000 | $58,250 | 5,000 |
| 2026-06-09 21:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | Officer | OPT+S | $240.09 | 33,000 | $7,922,970 | 42,867 |
| 2026-06-09 21:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $241.01 | 49,670 | $11,970,967 | 7,229 |
| 2026-06-09 20:48 | 2026-06-08 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $547.49 | 9,500 | $5,201,109 | 40,513 |
| 2026-06-09 20:49 | 2026-06-05 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Director | SELL | $34.54 | 10,000 | $345,351 | 51,884 |
| 2026-06-09 20:24 | 2026-06-05 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $450.00 | 1,745 | $785,250 | 21,015 |
| 2026-06-09 17:59 | 2026-06-08 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | OPT+S | $27.30 | 5,222 | $142,561 | 139,763 |
| 2026-06-09 16:04 | 2026-06-05 | AIMD | Ainos, Inc. | chiang yao-chung | Director | BUY | $2.05 | 3,500 | $7,175 | 11,279 |
| 2026-06-08 20:36 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Director | SELL | $10.73 | 2,625 | $28,166 | 10,958 |
| 2026-06-09 01:05 | 2026-06-08 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Director | SELL | $15.44 | 23,214 | $358,452 | 67,894 |
| 2026-06-09 01:11 | 2026-06-04 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | SELL | $16.27 | 169,427 | $2,756,984 | 109,850 |
| 2026-06-09 01:19 | 2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | Cannon Gillian | Director | SELL | $53.14 | 1,190 | $63,237 | 1,455 |
| 2026-06-09 01:19 | 2026-06-05 | XENE | Xenon Pharmaceuticals Inc. | PATOU GARY | Director | SELL | $53.14 | 1,322 | $70,251 | 24,896 |
| 2026-06-08 23:02 | 2026-02-13 | CING | Cingulate Inc. | Hargroves Thomas Jeffrey | Director | BUY | $5.04 | 97,276 | $490,271 | 97,468 |
| 2026-06-08 22:13 | 2026-06-04 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.41 | 105,565 | $43,028 | 377,211 |
| 2026-06-08 22:19 | 2026-06-05 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.06 | 735,462 | $45,599 | 0 |
| 2026-06-08 22:19 | 2026-06-04 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $0.08 | 843,622 | $64,115 | 505,302 |
| 2026-06-08 22:01 | 2026-06-04 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $67.67 | 80,000 | $5,413,288 | 4,318,447 |
| 2026-06-08 20:37 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Farzan Nima | Director | SELL | $10.73 | 2,625 | $28,166 | 9,767 |
| 2026-06-08 20:41 | 2026-06-04 | LQDA | Liquidia Corp | Manning Paul B | Director | SELL | $63.91 | 200,000 | $12,782,060 | 798,335 |
| 2026-06-08 20:30 | 2026-06-04 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $64.95 | 84,800 | $5,507,785 | 1,785,242 |
| 2026-06-08 20:33 | 2026-06-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $547.62 | 9,500 | $5,202,437 | 40,513 |
| 2026-06-08 20:01 | 2026-06-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer | OPT+S | $34.35 | 6,153 | $211,356 | 1,177,529 |
| 2026-06-08 20:01 | 2026-06-04 | GYRE | GYRE THERAPEUTICS, INC. | Ye Weiguo | Officer | OPT+S | $6.25 | 34,976 | $218,562 | 700,000 |
| 2026-06-08 18:53 | 2026-06-04 | PHVS | Pharvaris N.V. | Nijdam Anna | Officer | SELL | $30.87 | 2,670 | $82,425 | 46,275 |
| 2026-06-05 20:10 | 2026-06-03 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $17.48 | 2,500 | $43,700 | 22,500 |
| 2026-06-05 20:05 | 2026-06-03 | LFVN | Lifevantage Corp | BEINDORFF MICHAEL A | Director | SELL | $8.55 | 10,000 | $85,459 | 41,625 |
| 2026-06-05 20:14 | 2026-06-03 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $102.27 | 2,159 | $220,801 | 39,454 |
| 2026-06-05 20:11 | 2026-06-03 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | SELL | $102.90 | 4,424 | $455,248 | 60,486 |
| 2026-06-05 20:14 | 2026-06-03 | INSM | INSMED Inc | Bonstein Sara | Officer | SELL | $102.27 | 2,404 | $245,857 | 69,082 |
| 2026-06-05 20:12 | 2026-06-03 | INSM | INSMED Inc | Lewis William | Director, Officer | SELL | $102.27 | 7,605 | $777,763 | 265,432 |
| 2026-06-05 20:10 | 2026-06-03 | AIMD | Ainos, Inc. | chiang yao-chung | Director | BUY | $2.13 | 2,000 | $4,260 | 7,779 |
| 2026-06-05 22:29 | 2026-06-03 | XERS | Xeris Biopharma Holdings, Inc. | PERSKY MARLA | Director | SELL | $5.90 | 15,500 | $91,433 | 126,500 |
| 2026-06-05 22:17 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | JOHNSON JOHN | Director | SELL | $6.09 | 15,000 | $91,422 | 683,083 |
| 2026-06-05 22:18 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | SELL | $6.09 | 16,000 | $97,507 | 126,500 |
| 2026-06-05 22:18 | 2026-06-04 | XERS | Xeris Biopharma Holdings, Inc. | HALKUFF DAWN | Director | SELL | $6.09 | 20,000 | $121,886 | 95,000 |
| 2026-06-05 21:57 | 2026-06-04 | PCRX | Pacira BioSciences, Inc. | WILLIAMS KRISTEN | Officer | SELL | $22.27 | 10,259 | $228,468 | 167,062 |
| 2026-06-05 21:26 | 2026-06-03 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $4.37 | 8,285 | $36,209 | 173,224 |
| 2026-06-05 20:42 | 2026-06-04 | EQ | Equillium, Inc. | Connelly Stephen | Officer | SELL | $3.13 | 230,975 | $723,829 | 762,025 |
| 2026-06-05 20:42 | 2026-06-05 | EQ | Equillium, Inc. | Zedelmayer Christine | Officer | OPT+S | $2.93 | 14,584 | $42,737 | 62,586 |
| 2026-06-05 20:43 | 2026-06-03 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $30.01 | 2,645 | $79,376 | 20,439 |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $546.33 | 9,500 | $5,190,127 | 40,513 |
| 2026-06-05 20:31 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $546.28 | 10,000 | $5,462,824 | 18,876 |
| 2026-06-05 20:15 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Seth Alpna | Director | SELL | $10.72 | 2,625 | $28,140 | 9,767 |
| 2026-06-05 20:15 | 2026-06-03 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $102.27 | 2,370 | $242,380 | 98,603 |
| 2026-06-05 20:19 | 2026-06-03 | ALDX | Aldeyra Therapeutics, Inc. | Brady Todd C | Director, Officer | BUY | $1.67 | 250,000 | $418,450 | 1,721,298 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.